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y 24, 2013.his study sought to investigate the hypothesis that the favorable effects of mesenchymal stromal cells (MSCs) on
infarct repair are mediated by macrophages.Background The favorable effects of MSC therapy in myocardial infarction (MI) are complex and not fully understood.Methods We induced MI in mice and allocated them to bone marrow MSCs, mononuclear cells, or saline injection into the
infarct, with and without early (4 h before MI) and late (3 days after MI) macrophage depletion. We then analyzed
macrophage phenotype in the infarcted heart by ﬂow cytometry and macrophage secretome in vitro. Left ventricular
remodeling and global and regional function were assessed by echocardiography and speckle-tracking based strain
imaging.Results The MSC therapy signiﬁcantly increased the percentage of reparative M2 macrophages (F4/80þCD206þ) in the
infarcted myocardium, compared with mononuclear- and saline-treated hearts, 3 and 4 days after MI. Macrophage
cytokine secretion, relevant to infarct healing and repair, was signiﬁcantly increased after MSC therapy, or
incubation with MSCs or MSC supernatant. Signiﬁcantly, with and without MSC therapy, transient macrophage
depletion increased mortality 30 days after MI. Furthermore, early macrophage depletion produced the greatest
negative effect on infarct size and left ventricular remodeling and function, as well as a signiﬁcant incidence of left
ventricular thrombus formation. These deleterious effects were attenuated with macrophage restoration and MSC
therapy.Conclusions Some of the protective effects of MSCs on infarct repair are mediated by macrophages, which are essential for early
healing and repair. Thus, targeting macrophages could be a novel strategy to improve infarct healing and repair.
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3; revised manuscript received July 10, 2013,is impaired (1,2). Mesenchymal stromal cells (MSCs) have
been proposed to improve infarct repair (3), but their mech-
anism of action is complex and not fully understood (4,5).See page 1902One cell type with which MSCs might interact during
infarct healing is the macrophage (6). Although widely
recognized as contributors to the pathogenesis of atheroscle-
rosis, plaque build-up, andAMI,monocytes andmacrophages
also contribute to angiogenesis, infarct healing, and tissue
remodeling through their secretion of anti-inﬂammatory and
angiogenic cytokines (7–9). In previous studies, we found
macrophage collections at the sites of cell transplantation in
the infarct (4,10).Interestingly, despite very early and massive
loss of the transplanted cells, the favorable effects of cells on
left ventricular (LV) remodeling and function were preserved
(4,10). These unique phenomena motivated us to investigate
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1891the interaction between MSCs and macrophages during
infarct repair.
In response to activating signals, macrophages are “re-
educated” and become polarized into either a M1 phenotype
(proinﬂammatory) or M2 phenotype (anti-inﬂammatory).
The M1 macrophages are characterized by production of
proinﬂammatory cytokines including tumor necrosis factor
(TNF)-a and interleukin (IL)-1b, whereas M2 macropha-
ges are commonly associated with secretion of IL-10
(11–13). MSCs can modify macrophages from an M1 to an
M2 phenotype in vitro (14–17) and in vivo (18). However, it
is unclear whether macrophage modulation by MSCs
can affect infarct repair. Based on our work and that of
others, we hypothesized that the interaction between trans-
planted MSCs and infarct macrophages may play a role in
infarct repair, and could be exploited to improve LV
remodeling and function. The aim of the present study was
to test this hypothesis in a mouse model of MI.
Methods
Detailed descriptions of material and methods are presented
in the Online Appendix. The MSCs were isolated from
bone marrow (BM) of female Balb/C mice (age 12 weeks,
weight 20 g; Harlan, Jerusalem, Israel). To characterize the
BM MSCs, we harvested MSCs from the ﬁfth passage and
analyzed the cells by Calibur ﬂow cytometer (BD Biosci-
ences, San Jose, California). The MSCs of the ﬁfth passage
exhibited typical surface markers such as CD105 (44%) and
Sca-1 (82%), but not markers of hemotopoietic cells such
as CD45, CD31, TER-119, and F4/80. Furthermore,
these cells differentiated into adipocytes, osteoblasts, and
chondrocytes in vitro (Online Fig. 1).
To determine the role of macrophage subsets in infarct
repair and MSC therapy, female Balb/C mice were subjected
toMI by left main coronary artery occlusion (Online Table 1).
Then, we induced macrophage depletion by intravenous
injection of 0.1 ml clodronate liposomes (CL), either 4 h
before MI (early depletion) or on the third day after MI (late
depletion). Normal mice (n ¼ 5) received intravenous injec-
tions of CL using the same injection protocol to exclude the
possibility of a toxic effect of CL. One minute after artery
occlusion, the ischemic area was identiﬁed, and either MSCs
(1105), mononuclear cells (MNCs [1105]), or saline
(20 ml) were injected into the border zone. Conventional
echocardiography (1, 7, and 30 days after MI) and speckle-
tracking based strain imaging (1 and 7 days after MI) were
performed with a special echocardiography system (Vevo
2100 Imaging System, VisualSonics, Toronto, Ontario,
Canada), equipped with a 30 MHz phased transducer.
To determine macrophage subsets and the effect of
MSCs on macrophage polarization and function after MI,
we used ﬂow cytometry, enzyme-linked immunosorbent
assay, and RayBio mouse cytokine antibody array G series
(RayBiotech, Norcross, Georgia) exploring 62 different
cytokine proﬁles. To determine culture homogeneity, cellswere stained with anti-mouse
F4/80 or scrubbed and stained
withAPC-conjugated anti-mouse
F4/80 and analyzed by ﬂow
cytometry.
To determine the effect of
MSCs on infarct size, vasculari-
zation, and inﬂammation, we
harvested hearts 7 and 30 days
after injection (after the echocar-
diography imaging). Hearts were
sectioned and ﬁxed, and adjacent
blocks were embedded in parafﬁn
or optimal cutting temperature
compound (for cryosection) and sectioned into 5-mm slices.
Statistical analysis. Statistical analysis was performed with
the GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, California). All variables are expressed
as mean  SEM. Normality was tested with the
Kolmogorov-Smirnov test. The Mann-Whitney U test was
used (if data were not normally distributed) to compare
between 2 groups. Differences between baseline and 30 days
were assessed using 2-tail paired t tests. To test the
hypothesis that changes in measures of LV function between
1 and 30 days varied among the experimental groups,
a general linear model 2-way repeated-measures analysis of
variance was used. The model included the effects of treat-
ment, time, and treatment-by-time interaction. The Bon-
ferroni correction was used to assess the signiﬁcance of
predeﬁned comparisons at speciﬁc time points. Because of
the relatively small number of animals in each group,
echocardiography and speckle-tracking based strain imaging
at days 1 and 7, ﬂow cytometry, enzyme-linked immuno-
sorbent assay, and histology data were compared by Kruskal-
Wallis with Dunn’s multiple comparisons. A simple linear
regression analysis was used to estimate the relationship
between the number of MSCs and levels of IL-10 and
TNF-a. Survival among treatment groups was compared by
the log-rank (Mantel-Cox) test.Results
MSCtransplantation increasednumber ofM2macrophages
after MI. To characterize cardiac macrophage subsets in
the infarcted heart, we analyzed heart cells by ﬂow cytom-
etry at certain time points after MI. The number of
macrophages (F4/80þ cells) in the infarcted heart increased
progressively and peaked at day 4 after MI (Fig. 1A).
Notably, MSC transplantation reduced the percentage of
infarct macrophages (Fig. 1A).
Two macrophage subsets were identiﬁed in the infarcted
hearts: M1 macrophages characterized by double staining for
F4/80 and CD86, and M2 macrophages characterized by
double staining for F4/80 and CD206. Without interven-
tion, M1 macrophages were the dominant population
(>50%) on day 1 after MI, and their percentage remained
Figure 1 MSCs Increased Percentage of M2 Macrophages in the Infarcted Heart
(A) There was a signiﬁcant increase in macrophage (MF) accumulation in the infarcted heart in the ﬁrst 4 days after myocardial infarction (MI). However, mesenchymal stromal
cells (MSCs) reduced the number of macrophages in the infarcted heart. (B) The M1 percentage was not affected by MSCs. (C) The MSCs increased the M2 percentage. (D) The
MSCs increased the M2/M1 ratio 3 days after MI. The p value is based on Dunn’s multiple comparison test; p* value based on Mann-Whitney test; n ¼ 4 to 6. Red ¼ MSC;
black ¼ saline.
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1892relatively constant during the ﬁrst week after MI (Fig. 1B).
By contrast, the percentage of M2 macrophages in the
infarcted heart increased on day 4 (47  4%) and even more
so on day 7 (61  4%) after MI (p ¼ 0.04) (Fig. 1C).
Signiﬁcantly, MSC therapy increased the percentage of M2
macrophages by 63% and 52%, at 3 and 4 days after
MI, compared with control (Fig. 1C) (p < 0.01; p < 0.05).
Moreover, 3 days after MI, MSC transplantation increased
the M2/M1 ratio by 77%, compared with saline (p < 0.01)
(Fig. 1D). Interestingly, the percent of M1 plus M2 was
sometimes >100%, suggesting that during transition from
M1 to M2, some “intermediate” macrophages expressed
both M1 and M2 markers.
We then evaluated cytokine secretion from infarct
macrophages with and without MSC therapy. Macrophages
were isolated from the hearts, 3 days after MI and seeded on a
culture dish. After enrichment, we obtained 80% macro-
phages in culture (Online Figs. 2a and 2b). After 1 day in
culture, MSC-treated macrophages increased secretion of
anti-inﬂammatory cytokine IL-10 by 1.94-fold (Online
Fig. 2c.i), and Th2-related cytokines IL-5 and GM-CSFby 2.6-fold and 1.84-fold, compared with saline-treated
macrophages (Online Fig. 2c.ii and 2c.iii). Conversely, in
this experiment, TNF-a secretion was not affected by MSCs
(Online Fig. 2c.iv).
We next sought to determine whether the effect of
MSCs on infarct macrophage polarization was speciﬁc
or whether it could also be elicited by BM MNCs. We
found that although MSCs reduced the overall percentage
of macrophages (F4/80þ cells) in the infarcted heart by
33%, at day 3 after MI (9.8  1.8% vs. 14.5  1.3%, p ¼
0.08) (Fig. 2A), they signiﬁcantly increased the percentage
of M2 cells by 63% compared with saline (p < 0.01)
(Fig. 2C). By contrast, MNCs reduced the percentage
of M2 macrophages by 22% (Fig. 2C). The percentage
of M1 macrophages in the infarcted heart was not affected
by MSCs or MNCs (Fig. 2B). Subsequently, MSC
transplantation increased the M2/M1 ratio, by 66% and
77% compared with MNC transplantation and saline
injection (p < 0.05) (Fig. 2D). Thus, MSCs, but not
MNCs, switch infarct macrophages into a reparative (M2)
phenotype.
Figure 2 MSCs, But Not MNCs, Increased M2 Macrophage Percentage at Day 3 After MI
(A) Total macrophage (MF) percentage was reduced by mesenchymal stromal cells (MSCs). (B) The MSCs and mononuclear cells (MNCs) did not affect M1 percentage. (C) The
MSCs increased M2 percentage. (D) The MSCs increased M2/M1, whereas the MNCs did not. The p value is based on Kruskal-Wallis; p* value based on Dunn’s multiple
comparison test. MSC, n ¼ 6; MNC, n ¼ 5; saline, n ¼ 4. Red ¼ MSC; blue ¼ MNC; black ¼ saline.
JACC Vol. 62, No. 20, 2013 Ben-Mordechai et al.
November 12, 2013:1890–901 Mesenchymal Cells and Infarct Macrophages
1893MSCs modulated macrophage secretome in vitro. To
assess the interaction between macrophages and MSCs, we
co-cultured BM MSCs and peritoneal macrophages for
3 days. We found that MSCs stimulate IL-10 and TNF-a
secretion in a dose-dependent manner after 3 days (Online
Fig. 3). We then sought to determine the source of these
cytokines. We carried out an antibody-based protein array
analysis on 5 different culture groups (Online Table 2). Co-
cultures either with MSCs or MSC supernatant ampliﬁed
macrophage secretion of M2-related, reparative, and
angiogenic cytokines such as platelet factor 4 (involved in
wound healing) by 144% and 72%, and vascular endothelial
growth factor by 40%, compared with the sum of cytokine
secreted from macrophages plus MSCs. The highest levels
of reparative cytokines were obtained from a mixed culture
of macrophages and MSCs, suggesting that the interaction
was ampliﬁed by direct cell-to-cell contact. Interestingly, the
interaction between macrophages and MSCs also stimulated
secretion of IL-6 by 334% (Online Table 2). This cytokine
is typical for both M1 and M2b macrophages and also
relevant to tissue response to injury, healing and repair.
Additionally, MSCs increase or decrease the secretion of
cytokines that affect the immune system, particularly
lymphocyte activation (Online Table 2).Macrophage depletion attenuated the favorable effects
of MSC therapy. Signiﬁcantly, post-MI mortality after
30 days was highest after transient macrophage depletion in
control and MSC-treated groups (73% and 50%) (Fig. 3).
Infarcted mice with intact macrophages experienced lower
mortality, with and without MSC transplantation (15% and
35%) (Fig. 3). Furthermore, LV dilation was greatest and
contractility was lowest in surviving animals with macrophage
depletion, at days 1 and 30 after MI (Table 1). The MSC
therapy partially corrected these adverse effects of macro-
phage depletion (Table 1). Some of the early effects of tran-
sient macrophage depletion, for example its negative effect on
LV area, or the favorable effect of MSC transplantation on
LV remodeling and function, declined after 30 days (Table 1).
Because of the high mortality rate after a single dose of CL
(effective for 3 days), we avoided continuous administration
of the drug. Finally, macrophage depletion in another group
of normal mice was uneventful (Fig. 3).
To determine the role of macrophage subsets in phases
I and II after MI, we subjected another group of animals to
MI and early and late macrophage depletion, with and
without MSC therapy. Remarkably, early (4 h before
MI), but not late (3 days after MI), macrophage depletion
impaired LV function and increased LV dilation, at day 1 and
Figure 3 Macrophage Depletion Increased Mortality With and Without MSCs
Myocardial infarction (MI) after macrophage (MF) depletion was associated with high mortality. Mesenchymal stromal cell (MSC) therapy attenuated these negative effects. The
p value is based on the log-rank (Mantel-Cox) test. Normal animals-MF depletion (black), n ¼ 5; MI-MSC (blue), n ¼ 13; MI-saline (green), n ¼ 20; MI-MF depletion þ MSC
(gray), n ¼ 23; MI-MF depletion þ saline (red), n ¼ 35.
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18947 after MI (Table 2). For example, cardiac contractility,
presented by fractional area change and ejection fraction,
was lowest after early macrophage depletion, 1 and 7 days
after MI (Table 2). A week later, early depletion of macro-
phages increased diastolic and systolic LV areas by 30% and
68%, compared with saline (Table 2). Transplantation of
MSCs, with and without macrophage depletion, attenuated
adverse LV remodeling and dysfunction, 7 days after MI
(Table 2).
Deterioration of global and regional myocardial function
after MI and early macrophage depletion were conﬁrmed
by LV speckle-tracking based strain analysis (Table 3,
Fig. 4). Early macrophage depletion decreased regional
function of the infarct-related, apical and mid anterior
segments (Fig. 4A), which remained low after 7 days
(Table 3). Notably, MSC therapy after both early and late
macrophage depletion was associated with improved
regional function at the mid anterior infarct zone after
1 week (Table 3, Fig. 4B).
Interestingly, echocardiography studies, 1 week after MI,
revealed large LV thrombus after early but not late macro-
phage depletion (Fig. 5A). This unusual ﬁnding wasTable 1 Left Ventricle Remodeling and Dysfunction by Echocardiogra
MSCs
(n ¼ 11)
Saline
(n ¼ 9)
LV diastolic area, mm2 Day 1 after MI 8.6  0.3 8.9  0.4
Day 30 after MI 12.0  1.2 10.7  0.5
p (paired t test) 0.033 0.003
LV systolic area, mm2 Day 1 after MI 5.28  0.3* 5.58  0.5*
Day 30 after MI 7.1  0.5* 7.56  0.8
p (paired t test) 0.011 0.038
FAC, % Day 1 after MI 38.75  2.7* 37.64  3.4
Day 30 after MI 38.7  3.7 30.9  4.8
p (paired t test) 0.99 0.22
The p values are based on 2-way repeated-measures analysis of variance. *p < 0.05 versus saline þ e
CL ¼ clodronate liposomes; FAC ¼ fractional area change; LV ¼ left ventricle; MI ¼ myocardial infarcconﬁrmed by histological analysis (Fig. 5B). Signiﬁcantly,
MSC therapy reduced the incidence of LV thrombus,
compared with control (1 of 7 vs. 5 of 6 animals; p ¼ 0.03).
The imaging results were conﬁrmed by histological anal-
ysis. Masson’s-Trichrome staining revealed that MSCs
reduced infarct size by 40%, compared with saline (Fig. 6A).
Signiﬁcantly, early macrophage depletion, with and without
MSC therapy, was associated with the largest infarct size
(Fig. 6B). Infarct vascularization, as indicated by CD31 and
a-smooth muscle actin immunostaining 7 days after MI, was
more than 2-fold greater after early versus late macrophage
depletion (Online Fig. 4). This ﬁnding is probably related to
the number of macrophages with well-recognized angiogenic
properties at the time of evaluation. Remarkably, activity of
cathepsin B, L, and S, as markers of macrophage proteolysis,
was higher in saline-treated hearts with intact macrophages,
than in MSC-treated hearts, 7 days after MI (Fig. 7).Discussion
The major new ﬁnding of the present study suggests that
some of the favorable effects of MSCs on the infarctedphy at 1 and 30 Days After Myocardial Infarction
MSCsþEarly CL
(n ¼ 11)
SalineþEarly CL
(n ¼ 8) p Value
9.76  0.4 10.5  0.7 p interaction ¼ 0.73
p treatment effect ¼ 0.31
p time effect ¼ 0.003
14.6  3.2 13.2  0.8
0.15 0.034
6.16  0.2 8  0.8 p interaction ¼ 0.88
p treatment effect ¼ 0.004
p time effect ¼ 0.001
7.27  0.8 9.3  0.9
0.23 0.32
36.20  2 24.6  3.6 p interaction ¼ 0.32
p treatment effect ¼ 0.04
p time effect ¼ 0.6
42.9  6.5 30.2  3.7
0.34 0.3
arly CL, based on Bonferroni post-test.
tion; MSC ¼ mesenchymal stromal cell.
Ta
bl
e
2
E
ff
ec
t
of
M
S
C
Th
er
ap
y
on
G
lo
ba
l
LV
R
em
od
el
in
g
an
d
Fu
nc
ti
on
W
it
h
an
d
W
it
ho
ut
M
ac
ro
ph
ag
e
D
ep
le
ti
on
by
C
on
ve
nt
io
na
l
E
ch
oc
ar
di
og
ra
ph
y
at
1
an
d
7
D
ay
s
A
ft
er
M
yo
ca
rd
ia
l
In
fa
rc
ti
on
M
S
C
s
(n
¼
6
)
M
N
C
s
(n
¼
7
)
S
al
in
e
(n
¼
7
)
M
S
C
sþ
E
ar
ly
C
L
(n
¼
5
)
M
S
C
sþ
La
te
C
L
(n
¼
5
)
S
al
in
eþ
E
ar
ly
C
L
(n
¼
4
)
S
al
in
eþ
La
te
C
L
(n
¼
5
)
p
V
al
ue
*
LV
di
as
to
lic
ar
ea
,
m
m
2
D
ay
1
af
te
r
M
I
9
.7
2

0
.4
9
.9

0
.3
9
.2

0
.6
1
0

0
.5
9

0
.3
1
0
.3

0
.5
9
.1

0
.7
0
.2
8
D
ay
7
af
te
r
M
I
1
0
.8

0
.2
1
1
.1

0
.3
1
1

0
.6
1
2
.5

0
.8
9
.6

0
.1
1
4
.2
4

1
.8
1
0
.4

1
0
.0
6
LV
sy
st
ol
ic
ar
ea
,m
m
2
D
ay
1
af
te
r
M
I
5
.9

0
.6
6

0
.3
8
5

0
.6
6
.8

0
.4
6
.2

0
.4
7
.5

0
.5
5

0
.5
0
.0
4
D
ay
7
af
te
r
M
I
5
.8

0
.4
7

0
.4
6
.7

0
.5
7
.3

0
.9
5
.7

0
.4
1
1
.2
6

1
.6
6
.8

1
0
.0
7
FA
C
,
%
D
ay
1
af
te
r
M
I
3
9
.4

4
.2
3
2
.6

3
.9
4
5
.8

6
.3
3
5
.0
3

2
.6
3
0
.9
5

4
.5
2
7
.4
7

2
.3
4
5
.5

3
.7
0
.0
5
D
ay
7
af
te
r
M
I
4
5
.3
9

4
y
3
6

3
.9
3
7
.7
2

5
.3
4
1
.8
5

4
.7
4
1
.0
4

3
.5
2
1
.4
5

1
.8
3
6

5
0
.0
8
Ej
ec
tio
n
fr
ac
tio
n,
%
D
ay
1
af
te
r
M
I
5
1
.8
2

4
.4
4
4
.8

4
.2
6
1

6
.1
4
2
.2
4

5
.6
4
2

4
.8
3
9
.2
2

5
5
4
.9

4
.4
0
.0
7
D
ay
7
af
te
r
M
I
5
6
.7
6

4
.5
y
4
5
.8

2
4
6
.4

6
.2
4
4
.8

2
.6
5
0
.1
6

2
.3
3
3
.8

2
.5
4
4
.4

5
.9
0
.0
6
*T
he
p
va
lu
es
ar
e
ba
se
d
on
K
ru
sk
al
-W
al
lis
te
st
.
yp
<
0
.0
5
ve
rs
us
sa
lin
e
þ
ea
rly
C
L
at
da
y
7
af
te
r
M
I,
ba
se
d
on
D
un
n’
s
m
ul
tip
le
co
m
pa
ris
on
s.
A
bb
re
vi
at
io
ns
as
in
Ta
bl
e
1
.
JACC Vol. 62, No. 20, 2013 Ben-Mordechai et al.
November 12, 2013:1890–901 Mesenchymal Cells and Infarct Macrophages
1895myocardium are mediated by modulation of macrophage
phenotype and function. Transplantation of MSC into the
infarct decreases macrophage accumulation, and increases
the percentage of reparative (M2) macrophages in the
infarcted heart of mice. Furthermore, our in vitro experi-
ments suggest a cross-talk between macrophages and MSCs,
which results in augmentation of cytokine secretion.
Importantly, early macrophage depletion partially reduced
the favorable effects of MSC therapy after MI. Speciﬁcally,
early macrophage depletion increased infarct size and
mortality, accelerated adverse LV remodeling, dysfunction,
and LV thrombus formation early after MI. These negative
effects were attenuated by macrophage restoration and MSC
transplantation. In contrast, late (>3 day) macrophage
depletion was free of these negative effects. Taken together,
we propose an additional pathway by which MSCs could
improve infarct healing: modulation of infarct macrophage
function.
Our ﬁndings are important because they provide further
insight into the role of MSCs and macrophages in infarct
repair. The healing process after MI is believed to take place
with the transition of proinﬂammatory to reparative mac-
rophages (19). Excessive activation of inﬂammatory mono-
cytes and M1 macrophages worsens post-MI remodeling
(2,20). In the last few years, it has been recognized that
MSCs are modulators of immune response (5), and can
attenuate a systemic inﬂammatory response in animal
models of lung injury and sepsis (21). These protective
effects could be mediated by macrophages.
Our work adds to and extends recent publications
describing the role of monocytes and macrophages in infarct
repair (8,9,18,22–25). van Amerogen et al. (22) found that
macrophage depletion, in the ﬁrst week after cryoinjury in
mouse, markedly increased mortality, impaired infarct
healing, and accelerated adverse LV remodeling by post-
mortem histopathology. Nahrendorf et al. (8) showed that
2 distinct subsets of monocytes, the precursors of tissue
macrophages, participate in healing after MI in a sequential
manner. The CD11bhigh/Ly-6Chigh cells, exhibiting pha-
gocytic and proinﬂammatory functions, accumulate during
phase I (1 to 3 days), and CD11bhigh/Ly-6Clow cells,
attenuating an inﬂammatory response and expressing
vascular endothelial growth factor, are present during phase
II (4 to 7 days) (8).
Rapid monocyte turnover in the infarcted myocardium
has been reported. Leuscher et al. (24) found that within
days after injury, monocytes were recruited at a high rate but
resided only for an average of 20 h in the infarcted heart.
Thereafter most of the inﬁltrating monocytes become
apoptotic. Thus, soon after MI, Ly-6Chigh monocytes
inﬁltrated the infarct in large numbers (8,24). Many of these
monocytes do not necessarily differentiate to macrophages,
but rather exit or die in the tissue. Those that differentiate
acquire M1-like properties, continue to express Ly-6C, and
contribute to inﬂammation. Over time, as inﬂammation
gives way to resolution, a second Ly-6Cint/low phase emerges
Table 3 Effect of MSC Therapy With and Without Macrophage Depletion on Regional and Global LV Function by Speckle-Tracking Based Strain Imaging in Parasternal Long-Axis View
MSCs Saline MSCs+ Early CL MSCs+ Late CL Saline+ Early CL Saline+ Late CL p Value*
Peak longitudinal strain (n ¼ 6) (n ¼ 6) (n ¼ 5) (n ¼ 5) (n ¼ 4) (n ¼ 5)
Apical anterior, % Day 1 after MI 11.7  2.5 11.4  3.5 4.8  1.7 10.65  2.6 8.18  3.7 16.5  2.4 0.08
Day 7 after MI 7.7  1.9 11.4  3.2 4.7  1.2 15.4  4.4 4.2  2.3 17.81  2.5 0.026
Mid anterior, % Day 1 after MI 11.3  1.8 11.1  1.6 4.7  1.5 8.6  1.6 4.8  0.9 11.7  1.5 0.01
Day 7 after MI 9.3  1.3 7.8  1.6 6.4  1.5 12.05  1.8 7.1  1.3 9.56  1.7 0.2
Basal anterior, % Day 1 after MI 12  2.8 13.9  4.2 5.3  2.15 7.5  2.7 11.7  4.4 8  2.1 0.3
Day 7 after MI 6.88  2.2 4.2  1.6y 15.6  1.4 7.9  1.7 11.44  3.2 11.56  4.8 0.02
Global,z % Day 1 after MI 14  1.2 15  1.3y 7  1 11.5  1.4 9.1  2.4 14.4  2 0.01
Day 7 after MI 10.4  1.5 11.4  2.5 13.8  1.6 14.5  1.8 9.9  1.2 16  2.9 0.2
Peak radial strain (n ¼ 6) (n ¼ 7) (n ¼ 5) (n ¼ 5) (n ¼ 5) (n ¼ 6)
Apical anterior, % Day 1 after MI 22.52  4 20  4.6 9.1  2.9 22.38  5 17.64  10 35  7.2y 0.08
Day 7 after MI 17.54  4 22.2  5.55 7.4  3 34.26  11 9.8  4.2 24  5.8 0.07
Mid anterior, % Day 1 after MI 23.25  4.6 34  5.3 14.46  2.5 16.58  2.7 10  2.2 37.22  5x 0.007
Day 7 after MI 11.8  4.5 16.75  4.5 19.4  3.3 21.65  3.9 11.5  2.78 14.34  3.7 0.5
Basal anterior, % Day 1 after MI 28  10.37 41  0.12 30  8 32  9.3 18.91  5 20.4  2.1 0.8
Day 7 after MI 13.7  6 16.7  6.2 36.95  7.1 18.58  5 24.62  11 15.11  4.5 0.19
Global,z % Day 1 after MI 28.8  3.5 27.9  3.5 20.6  3.4 34.41  5 16.4  3.9 34.08  4.4 0.04
Day 7 after MI 17.11  3 23.6  4 28.73  3.8 36.38  7 18.3  1.8 26.96  3.4 0.07
*The p values are based on Kruskal-Wallis. yp < 0.05 versus MSCs + early CL, based on Dunn’s post-test. zWhole left ventricle average strain. xp < 0.05 versus saline + early CL, based on Dunn’s post-test.
Abbreviations as in Table 1.
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Figure 4 Representative Abnormal Apical-Anterior Strain Curves After MI and Macrophage Depletion
(A) Longitudinal and radial strain curves after myocardial infarction (MI) and early macrophage depletion show abnormal regional function and synchronization. (B) Longitudinal
and radial strain curves after MI, mesenchymal stromal cell (MSC) therapy, and late macrophage depletion show improved regional function and synchronization.
Endo ¼ endocardial.
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1897(8,24). The present study suggests that MSCs could affect
the kinetics of a macrophage subset after MI.
Nahrendorf et al. (8) also reported high cathepsin activity
among a Ly-6Chi subset. Our study expands upon these
ﬁndings and shows that MSCs increased the number of
reparative macrophages and decreased activity of cathepsin
B, L, and S in the infarct. Cathepsins have signiﬁcant
extracellular matrix proteolytic activity and can accelerate
adverse LV remodeling (26). Thus, attenuation of cathepsin
activity could be another pathway by which MSCs improve
LV remodeling and contractility after MI.
Another striking observation was LV thrombus formation
after early macrophage depletion and MI. The mechanism
of LV thrombus formation is unclear. Franz et al. (23)
who was the ﬁrst to describe LV thrombus complicating
macrophage depletion in acute MI, have suggested that LVthrombus could be related to a defect in infarct healing that
exposes damaged tissue to the blood. We found, for the ﬁrst
time, that MSC therapy markedly reduced the incidence of
LV thrombus after macrophage depletion, suggesting that
the development of LV thrombus is related to either
extensive MI or impaired healing, or both.
An alternative mechanism is MSC ﬁbrinolytic and
antithrombogenic properties. Neuss et al. (27) have shown
a high intrinsic ﬁbrinolytic capacity of hMSCs that medi-
ates the invasion into a ﬁbrin clot of a wounded tissue.
Agis et al. (28) have suggested that activated platelets
can enhance the plasminogen activation capacity of mesen-
chymal progenitors through the stimulation of uPA
production. Hashi et al. (29) have described attenuation of
platelet aggregation by MSCs. Thus, the low incidence
of LV thrombus after MSC transplantation could be
Figure 5 LV Thrombus Formation 1 Week After MI and Early Macrophage Depletion
(A) Large thrombus formation within the left ventricle (LV) by echocardiography: (i and ii) short-axis view; (iii and iv) long-axis view. (B) (i) macroscopic view of LV thrombus (T);
(ii) hematoxylin-eosin staining of LV thrombus.
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implanted cells.
Another potential pathway by which MSCs could correct
the harmful consequences of macrophage depletion, is
transdifferentiation: implanted MSCs could convert into
macrophages that restore healing and repair. For example,
Freisinger et al. (30) have described the potential of adipose-
tissue resident MSCs to generate functional macrophages
in vitro. Thus, theoretically MSCs could replace the
apoptotic macrophages and improve healing and repair.
Our results on the effect of MSCs on infarct macrophage
modulation support and extend recent ﬁndings of Dayan
et al. (18). They investigated the effect of 2 types of MSCs,
human BM-derived MSCs and human umbilical cord
perivascular cells, in an experimental MI model of the
immune-deﬁcient NOD/SCID mouse. Cells were infused
48 h after induction of MI, and mice assessed 24 h later
(72 h after MI) for BM, circulating, and cardiac tissue-
inﬁltrating monocytes/macrophages. Similar to our ﬁnd-
ings, they found that MSCs reduced the number of
macrophage/monocytes, whereas the proportion of M2
macrophages was increased in the circulation and heart.
Moreover, similar to our ﬁndings, fractional shortening was
improved 2 weeks after cell infusion, but was similar to
medium controls 16 weeks after MI. Our work conﬁrms and
adds to these ﬁndings in immune competent mouse by
showing that early macrophage depletion clearly attenuates
the therapeutic effects of MSCs. Additionally, we used
speckle-tracking based strain imaging to assess cardiac
function. Compared with conventional echocardiographic
imaging, speckle-tracking based strain echocardiography
efﬁciently detects delicate regional changes in cardiacperformance after MI and also identiﬁes early differences in
response to treatment (31).
The decline in the favorable effects of MSCs over time
might be related to either massive cell loss within 7 days after
transplantation (4) or to intensive monocyte and macro-
phage turnover in the infarcted tissue (24), or to both.
Together, the favorable effects of implanted MSCs are self-
limited and the disappearance of MSCs and “educated”
monocytes/macrophages from the infarcted heart reduced
the beneﬁcial effect over time.
Mechanism of macrophage polarization by MSCs. Des-
pite considerable attention, the speciﬁc molecular and
cellular mechanisms involved in macrophage polarization by
MSCs remain unclear. There is evidence that the ability to
modulate macrophage function relies on cells, contact-
dependent mechanisms, and paracrine effects through the
release of soluble factors (reviewed by Delarosa et al. [32],
Doorn et al. [33], and Krampera et al. [34]). First, MSCs
need to be “primed” by inﬂammatory cytokines to become
immunosuppressive (34). Then, it has been suggested
that a broad panel of molecular pathways are involved in
MSC-mediated macrophage regulation, including
interferon-g, IL-1b, indoleamine-2,3-dioxygenase, IL-4,
IL-6, IL-10, IL-13, prostaglandin-E2, TNF-a, nitric
oxide, heme oxygenase-1, hepatocyte growth factor, trans-
forming growth factor-b1, HLA-G5, as well as many other
factors, some of which are still unidentiﬁed (34). More
recently described molecules with immunoregulatory func-
tions includeCCL2, galectin-1, andTNF-a-stimulated gene/
protein-6. For example, expression of TNF-a-stimulated
gene/protein-6 was highly upregulated after infusion of
MSCs in mice with MI, and small interfering RNA (siRNA)
Figure 6 Effect of Macrophage Depletion and MSC Therapy on Relative Scar Area 1 Week After MI
(A)Masson’s-trichrome staining of mesenchymal stromal cell (MSC) or saline-injected hearts with intact macrophages or after macrophage depletion. (B) Comparison of relative
scar area among study groups. The p value is based on Kruskal-Wallis test; p* value based on Dunn’s post-test < 0.05. MSC, n ¼ 6; mononuclear cell (MNC), n ¼ 5; saline,
n ¼ 7; MSC þ early clodronate liposomes (CL), n ¼ 5; MSC þ late CL, n ¼ 5; saline þ early CL, n ¼ 5; saline þ late CL, n ¼ 4.
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fused MSCs on infarct size and heart function (35). Ad-
ditionally, MSCs may also modulate macrophage function
through the generation of regulatory T cells.
Finally, apoptosis of transplanted MSCs could account for
macrophage polarization (36). Apoptotic cell ingestion by
macrophages induces expression of anti-inﬂammatory
cytokines, such as IL-10 and transforming growth factor-b,
and could suppress synthesis of proinﬂammatory cytokines
in the infarcted heart (36). Indeed, we have shown that
intravenous infusion of apoptosis-mimicking liposomes
modulates macrophage phenotype and function, and
improves angiogenesis and infarct repair in rat (37).Thus, apparently, the mechanism responsible for macro-
phage regulation by MSCs is still unclear. Moreover, differ-
ences in the mechanisms of immunomodulation employed
by MSCs from different species have been reported (32).
Study limitations. First, cardiac macrophages isolated from
infarcted hearts were cultured in a purity of 80%. The F4/80
negative cells in culture are most likely ﬁbroblasts that could
affect the secretome. To adjust for this potential bias, we
compared infarct macrophages from saline-treated versus
MSC-treated hearts. Second, the high mortality rate after
early macrophage depletion and the relatively small number of
animals in certain experiments could create a selection bias.
Finally, the differences among groups were tested by several
Figure 7 MSC Inhibited Cathepsin Activity 1 Week After MI
Hearts were cryosectioned and labeled for cathepsin activity. Positive activity was detected by red ﬂuorescent color (arrows). CL ¼ clodronate liposomes; MI ¼ myocardial
infarction; MSC ¼ mesenchymal stromal cell.
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1900parameters. This could increase the risk of type I error (false
positive).
Conclusions
Our study emphasizes the critical role of monocyte/macro-
phage modulation in infarct repair, and proposes an addi-
tional pathway by which MSCs could improve infarct
healing: MSCs can act speciﬁcally at the macrophage level.
The importance of these ﬁndings lies in the fact that tar-
geting macrophages by MSCs or other means could be
a novel approach to ameliorate tissue injury not only in the
setting of MI but also in other diseases. Understanding the
signaling pathways and the fate of monocytes and macro-
phages after MI will support the search for speciﬁc therapies.
For example, intravenous infusion of apoptosis-mimicking
liposomes modulates macrophage phenotype and function,
and improves angiogenesis and infarct repair in rat (37).
Alternatively, silencing the chemokine receptor CCR2 gene
by siRNA inhibits the recruitment of inﬂammatory mono-
cyte subset in mice with MI, attenuates infarct inﬂamma-
tion, and limits post-MI LV remodeling (38).Taken together, the ability to improve infarct healing and
repair by monocyte/macrophage modulation could advance
the ﬁeld of cardiovascular regenerative medicine, particularly
in elderly and sick persons who have impaired immune
systems and regenerative potential.
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APPENDIX
For an expanded methods section, as well as supplemental tables and
ﬁgures, please see the online version of this article.
